Investor thesis
The category leader built a $8 bottle — and a trust problem.
feel free proved a two-ounce botanical shot can outsell Red Bull at a national convenience chain. Easy Days enters at the same price with the labeling and testing posture the category leader had to retrofit.
The case in numbers
Launch economics at the Q4 plan.
Plan case
Assumption — finalizingAfter trade
Assumption — finalizing64% of net
Assumption — finalizingOn $5.25 wholesale
Assumption — finalizingCategory evidence
What feel free (Botanic Tonics) has already proven.
feel free CLASSIC reached the No. 1 spot in the Energy & Supplement category at a top-five national convenience retailer (NIQ, week ending Oct 11, 2025).
Botanic Tonics press release, Oct 2025Distribution in over 27,000 stores and top-10 manufacturer status in the convenience energy category within three years.
Botanic Tonics press release, Oct 2024Raised $25M from existing cap-table investors to secure kava supply chain and fund testing protocols.
BevNET, Jan 2025Sells through an owned independent distributor network rather than large national distributors.
Botanic Tonics, Apr 2025Facing sustained consumer-harm and dependency coverage, plus a settled class action over addiction-risk disclosure — trust and labeling are the open flank.
Fortune, Dec 2025These are public, third-party or first-party published statements about Botanic Tonics — not Easy Days results.
The wedge
Four places we win the shelf conversation.
Full disclosure on the front of the bottle
The category's biggest liability is labeling. Easy Days states Kava + Kratom plainly, 21+, with dose and warnings up front. That is a buyer-safety argument, not just a marketing line.
Two SKUs, two legal footprints
Kava + Caffeine holds shelf where kratom is restricted. A one-SKU competitor loses the door entirely; Easy Days keeps the account.
Lab-tested every lot, published
Third-party testing per lot, made available to the buyer. Matches the compliance bar the category leader had to build after the fact.
Creator Collective instead of paid category ads
16.5% attributed commission on a 21+ creator roster — acquisition cost scales with sales instead of front-loading media spend.
Risk
What we tell investors before they ask.
Regulatory
Kratom is restricted in some states and the federal posture can move. Kava + Caffeine is the hedge — it keeps the account when Kava + Kratom can't ship.
Category reputation
Dependency and labeling coverage hits the whole category, not just the leader. Our answer is full front-label disclosure, 21+ enforcement, and published per-lot testing.
Distribution concentration
A distributor-led model means volume concentrates fast. The Q4 plan has to be spread across a named distributor target list before we commit production.
Ask
What the raise would fund.
Sizing follows the forecast, not the other way around. Once the Tuesday unit decision lands at 100,000 units, the use of funds resolves into four buckets: first production run and packaging, distributor slotting and launch trade, POS and creator content from the marketing budget, and the sales headcount to service the route.
Raise amount not set — awaiting the full forecast